Abstract
摘要
相似文献
1
Wider use for Enbrel.
FDA Consum. 2003 Nov-Dec;37(6):7.
2
Inhibition of tumor necrosis factor alpha and ankylosing spondylitis.
N Engl J Med. 2003 Jan 23;348(4):359-61; author reply 359-61.
3
Rapid remission of treatment-resistant ankylosing spondylitis with etanercept--a drug for refractory ankylosing spondylitis?
Arthritis Rheum. 2001 Aug;45(4):404. doi: 10.1002/1529-0131(200108)45:4<404::AID-ART355>3.0.CO;2-X.
4
[Anti-TNF alfa therapy in ankylosing spondylitis].
Acta Med Port. 2006 Mar-Apr;19(2):141-50. Epub 2006 Aug 18.
5
Etanercept (Enbrel) -- an update.
Skin Therapy Lett. 2004;9(10):1-4, 9.
6
Alopecia areata during etanercept therapy.
Ocul Immunol Inflamm. 2009 Mar-Apr;17(2):127-9. doi: 10.1080/09273940802596559.
7
Diverse effects of infliximab and etanercept on T lymphocytes.
Semin Arthritis Rheum. 2005 Apr;34(5 Suppl1):23-7. doi: 10.1016/j.semarthrit.2005.01.006.
8
Cost-effectiveness of etanercept in patients with severe ankylosing spondylitis in Germany.
Rheumatology (Oxford). 2010 Nov;49(11):2122-34. doi: 10.1093/rheumatology/keq222. Epub 2010 Jul 26.
9
[TNF-alpha inhibitors].
Rev Prat. 2003 Nov 30;53(18):1989-90.
10
Acute exacerbation of ankylosing spondylitis after chlamydial infection in a patient well-controlled with etanercept.
Int J Rheum Dis. 2012 Oct;15(5):e113-5. doi: 10.1111/j.1756-185X.2012.01748.x. Epub 2012 Apr 29.
Zotero 插件